ENTO
Price
$0.62
Change
-$0.00 (-0.00%)
Updated
Nov 12 closing price
MEOBF
Price
$0.99
Change
-$0.00 (-0.00%)
Updated
Nov 11 closing price
7 days until earnings call
Ad is loading...

ENTO vs MEOBF

Header iconENTO vs MEOBF Comparison
Open Charts ENTO vs MEOBFBanner chart's image
Entero Therapeutics
Price$0.62
Change-$0.00 (-0.00%)
Volume$46K
CapitalizationN/A
Mesoblast
Price$0.99
Change-$0.00 (-0.00%)
Volume$100
CapitalizationN/A
ENTO vs MEOBF Comparison Chart
Loading...
ENTO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
ENTO vs. MEOBF commentary
Nov 14, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ENTO is a StrongSell and MEOBF is a Buy.

COMPARISON
Comparison
Nov 14, 2024
Stock price -- (ENTO: $0.62 vs. MEOBF: $0.99)
Brand notoriety: ENTO and MEOBF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ENTO: 10% vs. MEOBF: 31%
Market capitalization -- ENTO: $3M vs. MEOBF: $1.14B
ENTO [@Biotechnology] is valued at $3M. MEOBF’s [@Biotechnology] market capitalization is $1.14B. The market cap for tickers in the [@Biotechnology] industry ranges from $473.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.83B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ENTO’s FA Score shows that 1 FA rating(s) are green whileMEOBF’s FA Score has 0 green FA rating(s).

  • ENTO’s FA Score: 1 green, 4 red.
  • MEOBF’s FA Score: 0 green, 5 red.
According to our system of comparison, ENTO is a better buy in the long-term than MEOBF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ENTO’s TA Score shows that 4 TA indicator(s) are bullish.

  • ENTO’s TA Score: 4 bullish, 5 bearish.

Price Growth

ENTO (@Biotechnology) experienced а -13.04% price change this week, while MEOBF (@Biotechnology) price change was +8.79% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.86%. For the same industry, the average monthly price growth was +5.66%, and the average quarterly price growth was +6.44%.

Reported Earning Dates

MEOBF is expected to report earnings on Feb 20, 2025.

Industries' Descriptions

@Biotechnology (-1.86% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MEOBF($1.14B) has a higher market cap than ENTO($3M). MEOBF YTD gains are higher at: 493.881 vs. ENTO (-85.238). ENTO has higher annual earnings (EBITDA): -20.9M vs. MEOBF (-62.82M). MEOBF has more cash in the bank: 62.6M vs. ENTO (11.4M). ENTO has less debt than MEOBF: ENTO (6.98M) vs MEOBF (119M). MEOBF has higher revenues than ENTO: MEOBF (5.9M) vs ENTO (0).
ENTOMEOBFENTO / MEOBF
Capitalization3M1.14B0%
EBITDA-20.9M-62.82M33%
Gain YTD-85.238493.881-17%
P/E Ratio0.05N/A-
Revenue05.9M-
Total Cash11.4M62.6M18%
Total Debt6.98M119M6%
FUNDAMENTALS RATINGS
ENTO vs MEOBF: Fundamental Ratings
ENTO
MEOBF
OUTLOOK RATING
1..100
8287
VALUATION
overvalued / fair valued / undervalued
1..100
10
Undervalued
88
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9793
PRICE GROWTH RATING
1..100
4135
P/E GROWTH RATING
1..100
7972
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ENTO's Valuation (10) in the null industry is significantly better than the same rating for MEOBF (88). This means that ENTO’s stock grew significantly faster than MEOBF’s over the last 12 months.

ENTO's Profit vs Risk Rating (100) in the null industry is in the same range as MEOBF (100). This means that ENTO’s stock grew similarly to MEOBF’s over the last 12 months.

MEOBF's SMR Rating (93) in the null industry is in the same range as ENTO (97). This means that MEOBF’s stock grew similarly to ENTO’s over the last 12 months.

MEOBF's Price Growth Rating (35) in the null industry is in the same range as ENTO (41). This means that MEOBF’s stock grew similarly to ENTO’s over the last 12 months.

MEOBF's P/E Growth Rating (72) in the null industry is in the same range as ENTO (79). This means that MEOBF’s stock grew similarly to ENTO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ENTO
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 13 days ago
82%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
86%
Aroon
ODDS (%)
Bullish Trend 2 days ago
76%
View a ticker or compare two or three
Ad is loading...
ENTO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RGPAX21.63N/A
N/A
RBC Global Opportunities A
GSBDX16.50N/A
N/A
Goldman Sachs Small Cap Growth A
BCSSX81.67-0.24
-0.29%
Brown Capital Mgmt Small Co Instl
BABSX8.99-0.03
-0.33%
BlackRock Global Equity Abs Rtn Instl
FIGCX19.35-0.38
-1.93%
Fidelity Advisor International Growth C

ENTO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ENTO has been loosely correlated with IVVD. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if ENTO jumps, then IVVD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENTO
1D Price
Change %
ENTO100%
-2.61%
IVVD - ENTO
60%
Loosely correlated
+0.46%
RLMD - ENTO
36%
Loosely correlated
+1.54%
CABA - ENTO
35%
Loosely correlated
-3.59%
IMMP - ENTO
29%
Poorly correlated
N/A
MEOBF - ENTO
24%
Poorly correlated
N/A
More

MEOBF and

Correlation & Price change

A.I.dvisor indicates that over the last year, MEOBF has been loosely correlated with SPHDF. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if MEOBF jumps, then SPHDF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MEOBF
1D Price
Change %
MEOBF100%
N/A
SPHDF - MEOBF
50%
Loosely correlated
N/A
AVTX - MEOBF
46%
Loosely correlated
-5.43%
COGT - MEOBF
39%
Loosely correlated
-0.19%
MESO - MEOBF
26%
Poorly correlated
+2.21%
KROS - MEOBF
26%
Poorly correlated
-4.92%
More